Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SP 16

Drug Profile

SP 16

Alternative Names: Serpin Peptide 16; SP-16

Latest Information Update: 03 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serpin Pharma
  • Developer Serpin Pharma; Virginia Commonwealth University
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antihyperglycaemics; Cardiovascular therapies; Oligopeptides; Peptides; Serpins; Skin disorder therapies
  • Mechanism of Action Immunomodulators; LDL receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Inflammation; Myocardial infarction; SARS-CoV-2 acute respiratory disease
  • Preclinical Acute kidney injury; Atopic dermatitis; Chronic inflammatory demyelinating polyradiculoneuropathy; Eosinophilic oesophagitis
  • Research Alopecia areata; Neuropathic pain; Pemphigus vulgaris
  • No development reported Diabetes mellitus; Myocardial reperfusion injury

Most Recent Events

  • 23 May 2024 Serpin Pharma terminates a phase I/II trial in SARS-COV-2 acute respiratory disease in USA (SC), due to lack of patients (NCT05135624)
  • 28 Jul 2022 SP 16 is still in phase-I/II trial for Myocardial infarction in USA (Serpin Pharma pipeline, July 2022)
  • 28 Jul 2022 Early research in Alopecia areata in USA (unspecified route) (Serpin Pharma pipeline, July 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top